SEMAX

Name: SEMAX
Brand: SEMAX
SKU: PEPT-SEMX-010
Availability: InStock

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Designed exclusively for laboratory research, this peptide exhibits neurotrophic, neuroprotective, and cognitive-enhancing properties without significant hormonal activity.

Unlike the parent ACTH molecule, Semax lacks corticosteroid-stimulating effects, making it a focused research tool for studying neuroplasticity, cerebral circulation, and neuronal repair mechanisms. Each lyophilized vial is synthesized to ≥98% purity, verified by independent HPLC and mass spectrometry. Researchers utilize Semax to investigate BDNF and NGF upregulation, antioxidant enzyme activity, and recovery following ischemic or hypoxic injury in preclinical models.

Key Features

High Purity: ≥98% confirmed by third-party HPLC analysis
ACTH (4-10) Analogue: Retains neurotrophic effects without corticosteroid activity
Neuroprotective Properties: Reduces oxidative stress and excitotoxicity in research models
Stable Lyophilized Format: Easy reconstitution for cell culture or preclinical research
Research Use Only: Not for human consumption, clinical use, or therapeutic application

Specifications

Specification	Detail
Molecular Formula	C₃₇H₅₁N₉O₁₀
Molecular Weight	781.85 g/mol
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro
Purity	≥98% (HPLC)
Appearance	White lyophilized powder
Storage (Lyophilized)	-20°C, protected from light and moisture
Storage (Reconstituted)	2-8°C for up to 7 days; aliquot for longer storage

Research Applications

Semax is widely used in preclinical studies investigating:

Ischemic & Hypoxic Injury: Stroke models, cerebral ischemia, and oxygen-glucose deprivation (OGD)
Neuroprotection: Excitotoxicity, oxidative stress, and mitochondrial preservation
Cognitive Enhancement: Learning, memory consolidation, and attention in rodent models
Neurotrophic Factor Research: BDNF, NGF, and GDNF expression in hippocampal and cortical tissues
Retinal Neuroprotection: Glaucoma and optic nerve crush models
Parkinson’s Disease Models: Dopaminergic neuron preservation in MPTP-induced toxicity

Typical Research Parameters

Parameter	Recommendation
Reconstitution	Sterile water or PBS (pH 7.0–7.4)
In Vitro Concentration	0.1–100 µM (neuronal or microglial cultures)
Preclinical Dosage (Rodent)	0.05–1 mg/kg, intranasal, intraperitoneal, or subcutaneous
Administration Frequency	Once daily or twice daily, depending on study design

Note: These are references for laboratory protocol design only, not medical dosing instructions.

Mechanism of Action

Semax exerts its research-documented effects through:

BDNF & NGF Upregulation: Increases mRNA and protein expression of neurotrophic factors in the hippocampus and cortex
Antioxidant Enzyme Activation: Enhances superoxide dismutase (SOD), catalase, and glutathione peroxidase activity
Cholinergic System Modulation: Increases acetylcholine levels and acetylcholinesterase regulation
Dopaminergic Protection: Reduces MPTP-induced dopaminergic neuron loss in Parkinson’s models
Cerebral Blood Flow Improvement: Modulates vascular tone and microcirculation in ischemic models
Anti-Inflammatory Effects: Reduces pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and NF-κB activation

Comparison: Semax vs. Related Peptides

Feature	Semax	Selank	Noopept (Dipeptide)
Amino Acids	7	7	2 (plus cyclization)
Origin	ACTH (4-10) fragment	Immunoglobulin G heavy chain	Racetam-like structure
Primary Mechanism	BDNF/NGF upregulation, antioxidant	Neurotrophins, cytokine modulation	AMPA receptor modulation
Primary Research Focus	Ischemia, neuroprotection, cognition	Anxiety, stress, and immune modulation	Neuroprotection, cognition
Hormonal Activity	None (ACTH-like activity removed)	None	None
Route of Administration (Preclinical)	IN, IP, SC	IN, IP, SC	Oral, IP